14/10/2022 (Agence Europe) – The European Health Emergency Preparedness and Response Authority (HERA) announced on Friday 14 October that the second European clinical trial for monkeypox using the antiviral Tecovirimat has been submitted to the European Medicines Agency (EMA). The trial was named EPOXI. HERA announced that EPOXI will use the clinical trial network for treatments funded by Horizon Europe, the EU’s research framework programme. The European Commission had announced on...